UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
Amendment No. 2
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 28, 2006
Pharma-Bio Serv, Inc.
(Exact name of registrant as specified in its charter)
Delaware 0-50956 20-0653570
-------- ------- ----------
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation) File Number) Identification No.)
373 Mendez Vigo, Suite 110, Dorado, Puerto Rico 00646
(Address of principal executive offices)
Registrant's telephone number, including area code: (787) 278-2709
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
Item 4.01 Changes in Registrant's Certifying Accountants.
As previously reported, on July 28, 2006, Kevane Soto Pasarell Grant
Thornton LLP ("Kevane") advised us that it is resigning as our independent
registered accounting firm as of the completion of the third quarter interim
review. On September 20, 2006, Kevane notified us that the auditor-client
relationship between Kevane and us terminated on September 20, 2006.
Kevane was the independent accountant for Plaza Consulting Group, Inc.
("Plaza") for the fiscal years ended October 31, 2005 and 2004. Kevane's report
for these periods did not contain an adverse opinion or disclaimer of opinion,
nor was it qualified or modified as to uncertainty, audit scope or accounting
principles. Plaza was acquired by Pharma-Bio Serv, Inc. (the "Registrant") on
January 25, 2006. During the two most recent fiscal years (for Plaza) and any
subsequent interim period (for the Registrant) through the date of resignation,
there were no disagreements with Kevane on any matter of accounting principles
or practices, financial statement disclosure or auditing scope or procedure,
which disagreements, if not resolved to the satisfaction of Kevane, would have
caused it to make reference to the subject matter of the disagreements in
connection with its reports.
On September 25, 2005, the Company engaged Horwath Velez & Co. PSC
("Horwath") as its registered independent accounting firm. The appointment of
Horwath was approved by our audit committee. As part of Horwath's engagement,
Horwath will also audit the financial statements of our pension plan. At no time
since its engagement has Horwath had any direct or indirect financial interest
in or any connection with us or any of our subsidiaries other than as
independent accountant.
Neither we, nor anyone on our behalf, consulted Horwath regarding the
application of accounting principles to a specific completed or contemplated
transaction, or the type of audit opinion that might be rendered on our
financial statements or either written or oral advice that was an important
factor considered by us in reaching our decision as to any accounting, auditing
or financial reporting issue.
Item 9.01 Financial Statements and Exhibits.
Exhibits
16.1 Letters from Kevane Soto Pasarell Grant Thornton LLP
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
PHARMA-BIO SERV, INC.
September 26, 2006 By: /s/ Manuel O. Morera
-----------------------------------------
Manuel O. Morera, Chief Financial Officer